title: Comparison of the efficacy of entecavir and tenofovir in chronic hepatitis B.
abstract: OBJECTIVE
  This study aimed to compare the efficacy of entecavir and tenofovir in nucleos(t)ide-naive chronic hepatitis B patients after 48 weeks of therapy.
  
  
  METHODS
  We retrospectively reviewed our data of chronic hepatitis B patients. Nucleos(t)ide-naive patients who had received entecavir or tenofovir for at least 48 weeks were included. We compared entecavir and tenofovir after 48 weeks of therapy with respect to virological, biochemical, serological and histological responses.
  
  
  RESULTS
  Of the 44 patients, 24 received entecavir and 20 received tenofovir. Pretreatment characteristics of the patients were similar. After 48 weeks, serum HBV DNA levels decreased by 6.93±1.54log copy/ mL in the entecavir group and 6.89±1.22log copy/mL in the tenofovir group (p=0.65). A similar proportion of patients in entecavir and tenofovir groups achieved undetectable serum HBV DNA (87.5% vs. 95%, p=0.39) and serum ALT normalization (79.2% vs. 85%, p=0.62). The mean histological activity index score improved by 3.83±3.51 points in the entecavir group and 2.20±1.91 points in the tenofovir group (p=0.07), and the mean fibrosis scores improved by 0.38±1.61 points in the entecavir group and 0.70±1.17 points in the tenofovir group after 48 weeks (p=0.44).
  
  
  CONCLUSIONS
  Entecavir and tenofovir are similarly effective in nucleos(t)ide-naive chronic hepatitis B patients with high viral load and/or high fibrosis scores after 48 weeks of therapy.
authors.affiliation: Department of Gastroenterology, Haysarpasa Numune Education and Research Hospital, Istanbul, Turkey. fguzelbulut@hotmail.com
authors.forename: Fatih
authors.initials: F
authors.lastname: Güzelbulut
authors.forename: Ayse Oya Kurdas
authors.initials: AO
authors.lastname: Ovünç
authors.forename: Züleyha Akkan
authors.initials: ZA
authors.lastname: Oetinkaya
authors.forename: Ebubekir
authors.initials: E
authors.lastname: Senates
authors.forename: Yasemin
authors.initials: Y
authors.lastname: Gökden
authors.forename: Ayça Gökçen Degirmenci
authors.initials: AG
authors.lastname: Saltürk
authors.forename: Mesut
authors.initials: M
authors.lastname: Sezikli
authors.forename: Selvinaz
authors.initials: S
authors.lastname: Ozkara
authors.forename: Fuat
authors.initials: F
authors.lastname: Cetinkaya
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D000704:Analysis of Variance; D000998:Antiviral Agents / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D001706:Biopsy; D016009:Chi-Square Distribution; D004279:DNA, Viral / Q000097:blood; D005260:Female; D006147:Guanine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006515:Hepatitis B virus / Q000235:genetics; D019694:Hepatitis B, Chronic / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D008103:Liver Cirrhosis / Q000473:pathology / Q000821:virology; D008297:Male; D008875:Middle Aged; D063065:Organophosphonates / Q000627:therapeutic use*; D012189:Retrospective Studies; D000068698:Tenofovir; D013997:Time Factors; D016896:Treatment Outcome; D019562:Viral Load
chemical_list: D000998:Antiviral Agents; D015415:Biomarkers; D004279:DNA, Viral; D063065:Organophosphonates; C413685:entecavir; D006147:Guanine; D000068698:Tenofovir; D000410:Alanine Transaminase; D000225:Adenine